Akynzeo (fosnetupitant 235mg, palonosetron 0.25mg) for injection has been made available by Helsinn for use in combination with dexamethasone for the prevention of acute and and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.
The intravenous formulation combines fosnetupitant (prodrug of netupitant), a substance P/NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist. It has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy.
Akynzeo for injection contains no antimicrobial preservatives and is intended for single use only. It is incompatible with any solution containing divalent cations (eg, calcium, magnesium), including Lactated Ringer’s Injection and Hartmann’s Solution; limited data are available on the compatibility of Akynzeo for injection with other IV substances, additives, or other medications.
Akynzeo is also available in capsule form (netupitant and palonosetron) for use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
For more information visit Akynzeo.com.